

# Cyrus R Mehta

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7527491/publications.pdf>

Version: 2024-02-01

65  
papers

7,312  
citations

186265  
28  
h-index

110387  
64  
g-index

69  
all docs

69  
docs citations

69  
times ranked

8500  
citing authors

#	ARTICLE	IF	CITATIONS
1	Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2013, 369, 1327-1335.	27.0	2,261
2	A Network Algorithm for Performing Fisher's Exact Test in Contingency Tables. <i>Journal of the American Statistical Association</i> , 1983, 78, 427-434.	3.1	729
3	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. <i>Lancet</i> , The, 2015, 385, 2067-2076.	13.7	659
4	A Randomized, Controlled Trial of Oral Propranolol in Infantile Hemangioma. <i>New England Journal of Medicine</i> , 2015, 372, 735-746.	27.0	601
5	Exact logistic regression: Theory and examples. <i>Statistics in Medicine</i> , 1995, 14, 2143-2160.	1.6	408
6	Adaptive Designs for Clinical Trials. <i>New England Journal of Medicine</i> , 2016, 375, 65-74.	27.0	335
7	Adaptive increase in sample size when interim results are promising: A practical guide with examples. <i>Statistics in Medicine</i> , 2011, 30, 3267-3284.	1.6	237
8	Exact Confidence Intervals Following a Group Sequential Test. <i>Biometrics</i> , 1984, 40, 797.	1.4	199
9	The potential role and rationale for treatment of heart failure with sodium-glucose cotransporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2017, 19, 1390-1400.	7.1	139
10	EXamination of Cardiovascular Outcomes with AlogliptIN versus Standard of Care in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE). <i>American Heart Journal</i> , 2011, 162, 620-626.e1.	2.7	138
11	Optimizing Trial Design. <i>Circulation</i> , 2009, 119, 597-605.	1.6	129
12	Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 1025-1036.	10.7	129
13	The future of drug development: advancing clinical trial design. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 949-957.	46.4	127
14	Sample Size Re-Estimation for Adaptive Sequential Design in Clinical Trials. <i>Journal of Biopharmaceutical Statistics</i> , 2008, 18, 1184-1196.	0.8	93
15	A hybrid algorithm for fisher's exact test in unordered rxc contingency tables. <i>Communications in Statistics - Theory and Methods</i> , 1986, 15, 387-403.	1.0	70
16	Flexible Sample Size Considerations Using Information-Based Interim Monitoring. <i>Drug Information Journal</i> , 2001, 35, 1095-1112.	0.5	70
17	Importance Sampling for Estimating Exact Probabilities in Permutational Inference. <i>Journal of the American Statistical Association</i> , 1988, 83, 999-1005.	3.1	68
18	Testing a Primary and a Secondary Endpoint in a Group Sequential Design. <i>Biometrics</i> , 2010, 66, 1174-1184.	1.4	58

#	ARTICLE	IF	CITATIONS
19	Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints. <i>Statistics in Medicine</i> , 2014, 33, 4515-4531.	1.6	54
20	Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: <sc>T</sc>he <sc>EXAMINE</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 664-671.	4.4	53
21	An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial). <i>Annals of Oncology</i> , 2019, 30, 103-108.	1.2	53
22	Exact Power of Conditional and Unconditional Tests: Going beyond the 2 × 2 Contingency Table. <i>American Statistician</i> , 1993, 47, 91-98.	1.6	48
23	Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial. <i>Diabetes Care</i> , 2016, 39, 1267-1273.	8.6	47
24	Adaptive, group sequential and decision theoretic approaches to sample size determination. <i>Statistics in Medicine</i> , 2006, 25, 3250-3269.	1.6	35
25	Repeated confidence intervals for adaptive group sequential trials. <i>Statistics in Medicine</i> , 2007, 26, 5422-5433.	1.6	34
26	Design and Monitoring of Multi-Arm Multi-Stage Clinical Trials. <i>Biometrics</i> , 2017, 73, 1289-1299.	1.4	33
27	Comparison of Exact, Mid-p, and Mantel-Haenszel Confidence Intervals for the Common Odds Ratio Across Several 2 × 2 Contingency Tables. <i>American Statistician</i> , 1992, 46, 146-150.	1.6	32
28	Exact Confidence Bounds Following Adaptive Group Sequential Tests. <i>Biometrics</i> , 2009, 65, 539-546.	1.4	32
29	Exact Stratified Linear Rank Tests for Ordered Categorical and Binary Data. <i>Journal of Computational and Graphical Statistics</i> , 1992, 1, 21-40.	1.7	31
30	Power comparisons for tests of trend in dose-response studies. <i>Statistics in Medicine</i> , 2000, 19, 3037-3050.	1.6	30
31	High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Tj ETQq1 1 0.784314 rgBT /Overlock 1 Metabolism. 2018. 20. 654-659.	4.4	30
32	Population Enrichment Designs: Case Study of a Large Multinational Trial. <i>Journal of Biopharmaceutical Statistics</i> , 2011, 21, 831-845.	0.8	26
33	Computational tools for exact conditional logistic regression. <i>Statistics in Medicine</i> , 2001, 20, 2723-2739.	1.6	24
34	Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (I): unknown correlation between the endpoints. <i>Statistics in Medicine</i> , 2012, 31, 2027-2040.	1.6	24
35	Exact inference for adaptive group sequential designs. <i>Statistics in Medicine</i> , 2013, 32, 3991-4005.	1.6	24
36	Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure. <i>Circulation</i> , 2018, 138, 1039-1053.	1.6	24

#	ARTICLE	IF	CITATIONS
37	An Exact Trend Test for Correlated Binary Data. <i>Biometrics</i> , 2001, 57, 941-948.	1.4	23
38	REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e61-e63.	3.0	23
39	EFFICIENCY ROBUST TESTS OF INDEPENDENCE IN CONTINGENCY TABLES WITH ORDERED CLASSIFICATIONS. <i>Statistics in Medicine</i> , 1996, 15, 2095-2105.	1.6	21
40	A Gatekeeping Procedure to Test a Primary and a Secondary Endpoint in a Group Sequential Design with Multiple Interim Looks. <i>Biometrics</i> , 2018, 74, 40-48.	1.4	16
41	An objective re-evaluation of adaptive sample size estimation: commentary on "Twenty-five years of confirmatory adaptive designs". <i>Statistics in Medicine</i> , 2016, 35, 350-358.	1.6	13
42	Optimal promising zone designs. <i>Biometrical Journal</i> , 2019, 61, 1175-1186.	1.0	12
43	Importance Sampling for Estimating Exact Probabilities in Permutational Inference. <i>Journal of the American Statistical Association</i> , 1988, 83, 999.	3.1	12
44	Economic Evaluation of Cost and Time Required for a Platform Trial vs Conventional Trials. <i>JAMA Network Open</i> , 2022, 5, e2221140.	5.9	12
45	Adaptive Sequential Testing for Multiple Comparisons. <i>Journal of Biopharmaceutical Statistics</i> , 2014, 24, 1035-1058.	0.8	10
46	Adaptive multiarm multistage clinical trials. <i>Statistics in Medicine</i> , 2020, 39, 1084-1102.	1.6	8
47	Blood and Urine Biomarkers Predicting Worsening Kidney Function in Patients with Type 2 Diabetes Post-Acute Coronary Syndrome: An Analysis from the EXAMINE Trial. <i>American Journal of Nephrology</i> , 2021, 52, 969-976.	3.1	8
48	Adaptive designs for noninferiority trials. <i>Biometrical Journal</i> , 2013, 55, 310-321.	1.0	6
49	Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial. <i>American Heart Journal</i> , 2016, 175, 18-27.	2.7	6
50	Efficiency Considerations for Group Sequential Designs with Adaptive Unblinded Sample Size Re-assessment. <i>Statistics in Biosciences</i> , 2018, 10, 405-419.	1.2	6
51	Some empirical comparisons of exact, modified exact, and higher-order asymptotic tests of independence for ordered categorical variables. <i>Communications in Statistics Part B: Simulation and Computation</i> , 1993, 22, 1-18.	1.2	5
52	Statistical Considerations for Cardiovascular Outcome Trials in Patients with Type 2 Diabetes Mellitus. <i>Statistics in Biopharmaceutical Research</i> , 2017, 9, 347-360.	0.8	5
53	Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome. <i>Clinical Cardiology</i> , 2018, 41, 1022-1027.	1.8	5
54	Optimal adaptive promising zone designs. <i>Statistics in Medicine</i> , 2022, 41, 1950-1970.	1.6	5

#	ARTICLE	IF	CITATIONS
55	Robust group sequential designs for trials with survival endpoints and delayed response. Biometrical Journal, 2022, 64, 343-360.	1.0	5
56	Adaptive clinical trial designs with pre-specified rules for modifying the sample size: a different perspective. Statistics in Medicine, 2013, 32, 1276-1279.	1.6	4
57	Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus. American Heart Journal, 2020, 229, 40-51.	2.7	4
58	A Consultant's Perspective on the Regulatory Hurdles to Adaptive Trials. Biometrical Journal, 2006, 48, 604-608.	1.0	3
59	Authors' response to "Comment on adaptive increase in sample size when interim results are promising". Statistics in Medicine, 2011, 30, 3302-3303.	1.6	3
60	Comments on "Some Challenges with Statistical Inference in Adaptive Designs" by Hung, Wang, and Yang. Journal of Biopharmaceutical Statistics, 2016, 26, 402-404.	0.8	3
61	Commentary on Freidlin and Korn. Clinical Trials, 2017, 14, 605-608.	1.6	3
62	Sample Size Reestimation for Confirmatory Clinical Trials. , 2012, , 81-108.		2
63	A simulation-based comparison of estimation methods for adaptive and classical group sequential clinical trials. Pharmaceutical Statistics, 2022, 21, 599-611.	1.3	2
64	Exact Inference for Adaptive Group Sequential Designs. Springer Proceedings in Mathematics and Statistics, 2019, , 131-139.	0.2	0
65	Monte Carlo Simulation for Trial Design Tool. , 2020, , 1-23.		0